Investor Presentation First Nine Months of 2023
15
Investor presentation
First nine months of 2023
Financial results - First nine months of 2023
Novo NordiskⓇ
In DKK million
Sales
Gross profit
Gross margin
First nine
months of 2023
166,398
First nine
months of 2022
128,862
Change
Change
(reported)
(CER)
29%
33%
Sales and distribution costs
140,647
84.5%
(39,573)
108,676
29%
34%
84.3%
(32,474)
22%
25%
Percentage of sales
23.8%
25.2%
Research and development costs
(21,983)
(15,962)
38%
39%
Percentage of sales
13.2%
12.4%
Administration costs
(3,399)
(3,119)
9%
11%
Percentage of sales
2.0%
2.4%
Other operating income and expenses
116
601
(81%)
(80%)
Operating profit
75,808
57,722
31%
37%
Operating margin
45.6%
44.8%
Financial items (net)
1,246
(4,976)
Profit before income tax
77,054
52,746
46%
Income taxes
(15,334)
(10,813)
42%
Effective tax rate
19.9%
20.5%
Net profit
61,720
41,933
47%
Diluted earnings per share (DKK)
13.71
9.21
49%
CER: Constant exchange ratesView entire presentation